Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $140

Benzinga Newsdesk www.benzinga.com Positive 82.4%

Neg 0% Neu 0% Pos 82.4%

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $130 to $140.